PDS Biotechnology grants employee stock options as inducement for employment.

From GlobeNewswire: 2024-12-06 08:00:00

PDS Biotechnology Corporation granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department on December 3, 2024, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and the Company’s 2019 Inducement Plan. Each stock option has an exercise price of $2.25, vests over a four-year period, and is based on the closing price of the company’s common stock on the grant date. PDS Biotech focuses on immunotherapy to target and kill cancers and develop infectious disease vaccines, with plans to initiate a pivotal clinical trial for advanced HPV16-positive head and neck squamous cell cancers.

Source: https://www.globenewswire.com/Tracker?data=Pig_Wpxi8WJFKY0S8ajM7Kn9BgEGn2E7Nq7ikAWyZtqJI4viDPxLxa6GrURIALS1qQ2x4JtyNzA1NWIfw3HfhGzSwdcEe19Hm-ErmkKXe_A

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation. Forward-looking statements in the communication discuss the Company’s plans, trends, and expectations for future operations based on current management beliefs and available information. Factors such as protecting intellectual property, funding clinical trials, and interpreting results may impact actual results. The Company undertakes no obligation to revise or update forward-looking statements and relies on collaboration studies to advance product candidates effectively.

Source: https://www.globenewswire.com/Tracker?data=xGubph_Hq6d6ZOOwZrTsiEJv1BZWYyLAcUlZDGbqdXM1J5IBqBdoj7eIcxs_SnS0xqaUEJFAANjPJnXACl0NjF-XjMnJ_eopeHo7Eynn870



Read more at GlobeNewswire: PDS Biotechnology Reports Inducement Grant Under Nasdaq